Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Creative Commons License

Mutlu Y. G., Yıgıt Kaya S., Maral S., Melek E., Başlar Z., Kaynar L., ...More

FRONTIERS IN IMMUNOLOGY, vol.14, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2023
  • Doi Number: 10.3389/fimmu.2023.1276295
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Directory of Open Access Journals
  • Keywords: Elranatamab, multiple myeloma, bispecific Ab, BCMA, CNS involvement
  • Istanbul Medipol University Affiliated: Yes


Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.